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Constitutive Rac Activation Is Not Sufficient to
Initiate Melanocyte Neoplasia but Accelerates
Malignant Progression
Lucy E. Dalton1,4,5, Jivko Kamarashev2,5, Irene Barinaga-Rementeria Ramirez3, Gavin White1,
Angeliki Malliri1,6 and Adam Hurlstone3,6
Deregulated Ras signaling initiates and maintains melanocyte neoplasia. The Rho-like GTPase Rac has been
implicated in Ras-induced neoplastic transformation. Moreover, a recurrent UV-induced mutation activating
RAC1 has recently been detected in human melanoma. Here, a role for Rac in melanoma initiation and
progression was investigated in human melanomas and zebrafish models of melanocyte neoplasia. Immunohis-
tochemical analysis revealed RAC expression and activity restricted to melanocytes at the junction of the
epidermis and dermis in benign neoplasms. Malignant melanocytes displayed elevated RAC activity that
extended into the suprabasal epidermis, deeper into the dermis, and was maintained in metastases. Previously,
we have used zebrafish transgenic models to demonstrate that deregulated Ras/Raf/mitogen-activated protein
kinase signaling can initiate melanocyte neoplasia. Expression of a constitutively active RAC1 mutant (V12RAC1)
was not sufficient to initiate melanocyte neoplasia in this organism. Furthermore, we did not detect an additive
effect when combined with V600EBRAF, nor could V12RAC1 substitute for suppressed Pi3k signaling to restore
melanoma progression. However, coexpression of V12RAC1 and oncogenic RAS accelerated tumor nodule
formation. Immunohistochemical analysis revealed that the Rac activator Tiam1 (T-cell lymphoma invasion and
metastasis 1) is overexpressed in melanoma tumor nodules in both zebrafish and humans. Thus, our data suggest
that Rac contributes to the progression of melanoma and that Tiam1 may activate Rac in nodular presentations.
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INTRODUCTION
The Rho-family small guanine nucleotide triphosphate hydro-
lase (GTPase) Rac cycles between an active GTP-bound form
and an inactive guanosine diphosphate–bound form. Guanine
nucleotide exchange factors (GEFs) activate GTPases by
catalyzing the replacement of guanosine diphosphate with
GTP. The Dbl-family Rho GEF, Tiam1, selectively activates
Rac (Michiels et al., 1995). Rac stimulates cellular processes
deregulated in neoplasia such as proliferation, survival,
motility, and invasiveness (Mack et al., 2010), thereby
functioning as an oncogene in cellular transformation assays
in cooperation with the Ras effector c-Raf and being required
for Ras-induced transformation (Khosravi-Far et al., 1995; Qiu
et al., 1995). RAC1 expression and activity is increased in
human malignancies (Jordan et al., 1999; Schnelzer et al.,
2000; Kamai et al., 2004; Pan et al., 2004). Furthermore, rac1
conditional knockout mice are resistant to the formation of
lung adenocarcinoma driven by oncogenic Kras (Kissil et al.,
2007) and the formation of skin tumors driven by oncogenic
Hras (Wang et al., 2010), similar to Tiam1 (T-cell lymphoma
invasion and metastasis 1)-deficient mice (Malliri et al.,
2002b). More recently, selective deletion of the rac1 gene
was shown to reduce the anchorage-independent growth,
proliferation, migration, invasion, and ability to form
metastatic tumor xenografts of immortalized mouse
melanocytes expressing oncogenic Nras (Li et al., 2012).
Significantly, a recurrent, presumably UVB-induced, C4T
transition at coding nucleotide 85 of the human RAC1 gene
has been identified in B4% of all melanomas (Hodis et al.,
2012), and 9% of sun-exposed melanomas specifically, with
the mutation not being detected in melanomas from sites
shielded from the sun (Krauthammer et al., 2012). This
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mutation results in the substitution of proline at position 29 for
serine, conferring a conformational change on the switch I loop,
resulting in a more avid binding to effectors such as p21-
activated kinase 1 (PAK1; Krauthammer et al., 2012). After
valine at position 600 of BRAF and glutamine at position 61 of
NRAS, proline 29 of RAC1 is the most frequently mutated amino
acid in melanoma. The frequency of P29S mutation was similar
in primary and metastatic tumors, suggesting that the mutation
arises early in the formation of melanoma (Krauthammer et al.,
2012). The mutation occurred in conjunction with NRAS and
BRAF mutations, as well as independently of these mutations
(Hodis et al., 2012; Krauthammer et al., 2012), suggesting that it
confers growth advantages distinct from activation of the RAS/
RAF/mitogen-activated protein kinase signaling pathway. In this
study, we address how widespread are changes in RAC activity
during neoplastic transformation of human melanocytes and,
using transgenic zebrafish models, whether constitutive RAC
activation can initiate neoplasia in melanocytes or contribute to
melanoma progression.
RESULTS AND DISCUSSION
Rac activity increases with melanoma progression in vivo
RAC expression and activity were analyzed in human mela-
nocytic neoplasms (29 benign and 31 malignant lesions) by
performing immunohistochemical analysis with two indepen-
dent antibodies: one recognizing total RAC (Woodcock et al.,
2010) and a conformational antibody recognizing specifically
GTP-bound RAC (that is, active RAC). We confirmed the
selectivity of the RAC–GTP antibody for active RAC
(Supplementary Figure S1a and b online; see also (Samuel
et al., 2011)). In all cases, staining for total RAC and RAC–GTP
was analogous, although staining with the RAC–GTP antibody
was consistently more intense (for a representative example
see Supplementary Figure S1c online). Thus, in tissues, RAC
activity correlated with RAC expression level. Furthermore,
RAC was overexpressed and hyperstimulated in melanoma
relative to benign lesions (Figure 1a). Overexpression was
observed even in superficial spreading melanoma with Bre-
slow depth of o0.75 mm that could be considered radial
growth phase (RGP) melanoma (as evident for the example in
Supplementary Figure S1c online). Moreover, as summarized
in Supplementary Table S1 online, distinct patterns of staining
in nevi and in malignant melanoma were observed (depicted
only for RAC–GTP in representative images in Figure 1c–g). In
normal skin, only the basal cell layer of the epidermis
stained strongly for total RAC and RAC–GTP (Figure 1b; see
also (Benitah et al., 2005)). In nevi, additional staining was
observed in nests of nevocytes but only at the junction
between the epidermis and dermis (Figure 1c, arrowheads).
Dysplastic nevi showed a somewhat stronger staining than in
nevi without atypia, but the pattern was otherwise similarly
restricted to the junctional zone (Figure 1d). Furthermore,
neither total RAC nor RAC–GTP expression was detected in
nevocytes of purely dermal nevi (not shown). The junctional
zone between the epidermis and dermis is considered a region
of active proliferation in nevi, and early melanoma always
develops at this junctional zone. In melanomas, total RAC and
RAC–GTP expression is observed both suprabasally in the
epidermis (where malignant melanocytes are also typically
found, so-called Pagetoid spread; arrows in Figure 1e and f)
and in the dermal invasive component, although heteroge-
neously (arrowheads in Figure 1e and f). Metastases also
frequently displayed heterogeneous staining (an example is
shown in Figure 1g) but were occasionally completely
negative. Rac1 is the major ubiquitous isoform of Rac
expressed in mammalian tissues and is the only Rac isoform
expressed in mouse melanocytes (Li et al., 2011). Rac2 is
considered to be specifically expressed in the blood and Rac3
largely in the nervous system (Corbetta et al., 2005). We
assume therefore that human melanocytes and, by extension,
melanoma cells express predominantly RAC1.
RAC activity levels were next measured by pull down of the
GTP-bound form of RAC (see Materials and Methods) in a
panel of human cell lines comprising primary human neona-
tal melanocytes moderately pigmented (HEMn-MP), immor-
talized but nontumorigenic melanocytes (Hermes 2B and
Hermes 4A), a cell line derived from RGP melanoma
(WM35), cell lines derived from vertical growth phase
(VGP) melanoma (WM98-1, WM1158, and Mel Juso), and
from melanoma metastases (WM266-4, SKMEL28, A375P,
MM485, and WM1361). This analysis revealed elevated RAC
activity in all melanoma cell lines relative to primary
melanocytes and immortalized melanocytes (Figure 2a),
again consistent with increased RAC activity being implicated
in malignant progression. As the melanoma cell line panel
comprises both NRAS (Mel Juso, MM485, and WM1361) and
BRAF mutant lines (the rest), the elevated RAC activity
correlated with malignancy and not mutation status. Simi-
larly, the tumors stained above, which were selected at
random, will comprise examples of both oncogenic BRAF-
and NRAS-transformed cells, implying that RAC overexpres-
sion and hyperstimulation in melanoma reflect malignant
status and not simply activation by oncogenic NRAS.
Melanocyte neoplasia can be induced in zebrafish. Zebra-
fish expressing oncogenic V600EBRAF in their melanocytes
display hyperplasia only; progression to melanoma can be
elicited through inactivation of the tumor-suppressor p53
(Patton et al., 2005). We have demonstrated that animals
expressing G12VHRAS develop melanocyte hyperplasia
accompanied by an increased progenitor compartment, as
well as infrequent invasion of the epidermis and loose
connective tissue of the dermis and subcutaneous tissues by
melanocytes. We classified this presentation as RGP
melanoma in zebrafish. Furthermore, this condition can
spontaneously progress to VGP melanoma (Michailidou
et al., 2009). In both the V600EBRAF;p53 / and
G12VHRAS models, the VGP manifests largely as malignant
tumor nodules (Patton et al., 2005; Michailidou et al., 2009),
whereas in humans VGP arises largely in the context
of superficial spreading melanoma but also manifests
as malignant tumor nodules (Warycha et al., 2008). Protein
was extracted from the skins of wild-type, V600EBRAF;p53 / ,
and V12HRAS animals and tumor nodules from
V600EBRAF;p53 / and V12HRAS animals and subjected to
a G-LISA assay for measurement of active Rac (see Materials
and Methods). Rac activity levels were increased by 20% in the
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skins of V600EBRAF animals (benign) and by 70% in the skins
of V12HRAS animals (RGP) compared with wild-type animals
(Figure 2b). RAC–GTP levels were also elevated in tumor
nodules (VGP) from both V600EBRAF;p53 / and V12HRAS
animals (Figure 2b). Thus, Rac activity in our zebrafish
melanoma models also correlates with the progression to
malignancy, manifesting first in the RGP.
Constitutive Rac activation does not initiate melanocyte
neoplasia
To address whether constitutive Rac activation can initiate
melanocyte neoplasia, we generated zebrafish transgenic lines
overexpressing Myc-tagged human RAC1, which has a valine
for glycine substitution at position 12 (hereafter referred to as
V12RAC1), rendering it constitutively active, again under the
control of the zebrafish mitfa promoter. To aid in the
identification of transgenic offspring, the plasmid also con-
tained a second expression cassette comprising green fluor-
escent protein (GFP) complementary DNA (cDNA) coupled to
the zebrafish keratinocyte–specific krt4 promoter (Figure 3a).
Transgenic F1 could easily be identified and isolated from
nontransgenic siblings at 24 hours after fertilization because of
GFP expression (Figure 3b). Two different founder fish were
isolated that gave rise to two independent transgenic lines,
V12RAC1 line 1 and line 2. Transgenic F1 embryos displayed
no perturbation in melanocyte patterning or morphology
Compound nevus
Compound nevus
Dysplastic compound nevus
Superficial spreading melanoma
Nodular melanoma Metastatic melanoma
Melanoma
Normal skin
epi
der
Figure 1. RAC activity in human melanocyte neoplasms. (a) Total RAC or (b–g) RAC–GTP (pink/red stain) in (b) normal skin or (a, c–g) melanocyte neoplasms as
indicated. (a) A complex lesion in which superficial spreading melanoma is observed adjacent to an area of compound nevus. Note the increased total RAC
staining within the area of melanoma and its spread to suprabasal epidermal layers. Arrowheads in (c) point to positive nests of nevocytes at the junction between
the epidermis (epi) and dermis (der). Arrows in (e) and (f) point to positive melanoma cells in suprabasal epithelium, whereas arrowheads indicate positive
melanoma cells in the dermis.
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during development, and similarly no alteration in the
pigmentation pattern was observed in adults (Figure 3c).
Expression of the transgene was confirmed by reverse
transcriptase–PCR analysis of RNA prepared from embryos
(Figure 3d). Immunohistochemical staining of embryo sections
revealed increased activation loop phosphorylation of the Rac
effector Pak in V12RAC1-expressing melanocytes compared
with wild-type melanocytes (Figure 3e), signifying Pak activa-
tion, consistent with increased Rac signaling in these cells.
Immunoblotting skin protein lysates from adult zebrafish with
an anti-Myc antibody confirmed V12RAC1 expression
(Figure 3f). Rac activity levels were also measured in lysates
prepared from the skin of transgenic F1 animals using G-LISA,
in which statistically significant increases of 22% and 16%
were observed in V12RAC1 lines 1 and 2, respectively,
compared with wild-type sibling controls (Figure 3g).
Considering that the melanocytes expressing the transgene
represent only a small proportion of the cells in the skin,
and thus correspondingly contribute only a fraction of the total
Rac activity, the increase in Rac activity in melanocytes is
likely to be even greater.
Coexpression of active Rac does not result in malignant
progression of benign neoplastic melanocytes
Constitutively active c-Raf and constitutively active Rac1
cooperate to transform fibroblasts (Qiu et al., 1995). We
hypothesized that the coexpression of V600EBRAF and
V12RAC1 might thus synergize to induce malignancy in
melanocytes and potentially produce a phenotype similar to
V12HRAS-expressing zebrafish. To test this, we crossed
V12RAC1 lines 1 and 2 with V600EBRAF animals and analy-
zed the transgenic offspring. No perturbation of the benign
phenotype was observed in double-transgenic offspring
(Supplementary Figure S2a online). The above findings indi-
cate that stimulating Rac signaling in an otherwise benign
context is not sufficient to promote progression to VGP.
In addition to mitogen-activated protein kinase signaling,
Ras stimulates phosphoinositide 3-kinase (Pi3k) signaling, and
an increased PI3K signaling is also implicated in the malignant
progression of melanocyte neoplasms (Madhunapantula et al.,
2011). Dbl family Rac GEFs possess Pleckstrin homology
domains and are recruited to the plasma membrane by
phosphatidylinositol (3,4,5)-triphosphate generated by PI3K
to activate Rac. To test whether V12RAC1 could suffice for
Pi3k signaling in promoting malignant progression, we crossed
V12RAC1 lines with animals coexpressing V12HRAS and a
mutant-regulatory domain of Pi3k, Dp85, which antagonizes
Pi3k signaling. As with V600EBRAF, V12HRAS- and Dp85-
coexpressing animals display benign melanocyte hyperplasia
only (Michailidou et al., 2009). Again, no augmentation of the
benign phenotype was observed in double-transgenic
offspring (Supplementary Figure S2b online), suggesting that
V12RAC1 cannot substitute for impaired Pi3k signaling in
promoting progression to melanoma.
Active Rac accelerates tumor nodule onset
From staining human melanomas, RAC expression appeared
heterogeneous. Potentially, increasing the frequency of cells
with intense and sustained Rac signaling would influence the
rate of melanoma progression. To test this hypothesis, we
crossed V12RAC1 lines 1 and 2 with V12HRAS animals and
monitored phenotypic changes over 16 weeks. Coexpression
of V12HRAS and V12RAC1 significantly decreased the med-
ian time to onset of tumor nodules compared with V12HRAS-
alone animals (Figure 4a). These observations were more
pronounced in V12RAC1 line 2, with only B42% of animals
being tumor-free at 16 weeks compared with 75% in
V12RAC1 line 1 and 90% of V12HRAS-only animals. Early
onset of tumor was also reflected by monitoring tumor growth
in V12RAC1 lines (Figure 4b). However, the growth rate of
individual tumor nodules in V12HRAS::V12RAC1 double-
transgenic animals compared with V12HRAS-alone fish was
not significantly different (data not shown). Figure 4c shows
typical examples of a V12HRAS-alone animal and a
V12HRAS::V12RAC1 line 2 animal with multiple malignant
tumor nodules. As anticipated, V12HRAS::V12RAC1 trans-
genic animals demonstrated increased staining for RAC–GTP
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Figure 2. Rac activity levels in human melanoma cell lines and at different
stages of melanoma in zebrafish. (a) RAC activity in a panel of human
melanoma cell lines, as well as immortalized benign melanocytes and primary
melanocytes, as established by pull down of RAC–GTP. RAC–GTP/total RAC
ratios for the various cell cultures relative to Hermes 2B are indicated beneath
these representative western blots from three independent experiments. (b) Rac
activity levels in the skins from wild-type (WT), V600EBRAF, and V12HRAS
animals, as well as tumor nodules (vertical growth phase (VGP)) from
V600EBRAF;p53 / and V12HRAS animals, as determined by G-LISA. The
mean of six independent samples±SEM expressed relative to WT. *Po0.05,
**Po0.01; one-way analysis of variance (ANOVA).
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in tumors compared with V12HRAS-alone animals (Supple-
mentary Figure S3a online). Furthermore, we detected
increased Pak activation loop phosphorylation in tumors
from V12HRAS::V12RAC1 transgenic animals, indicative
of increased Rac signaling in these cells (Supplementary
Figure S3a online). This corresponds with increased Rac
activity in the skin as measured by G-LISA (Supplementary
Figure S3b online). V12HRAS::V12RAC1 animals display
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Figure 3. Constitutive activation of Rac signaling does not initiate melanocyte neoplasia. (a) Schematic representation of the construct generated with Myc-
V12RAC1 under the control of the mitfa promoter and green fluorescent protein (GFP) under the krt4 promoter. (b) Transgenic zebrafish embryo at 24 hours after
fertilization expressing GFP together with a wild-type sibling (WT sib.). The left panel shows brightfield image and the right panel shows epifluorescent image.
Scale bar¼100mm. (c) Left panels show wild-type (WT sib.) and transgenic (V12RAC1) zebrafish larvae at 5 days after fertilization. Bars¼ 100mm. Right panels
show adult zebrafish. Bars¼ 1 cm. (d) Reverse transcriptase–PCR (RT–PCR) analysis at 24 hours after fertilization demonstrating mRNA expression of exogenous
Myc-tagged V12RAC1 and GFP. Without RT (reverse transcriptase) controls ( ). Elongation factor-1a (EF1a) is used as a control for complementary DNA (cDNA)
integrity and equal loading. (e) Transverse cross-sections through PTU-treated 3 days after fertilization wild-type (WT) and V12RAC1 line 1 embryos
immunostained for Pak phosphorylated on its activation loop (pink/red stain). Arrows point to position of melanocytes. Bars¼25mm. (f) Myc-tagged V12RAC1
protein expression in skin from two transgenic lines (V12RAC1 lines 1 and 2) and nontransgenic wild-type siblings (WT sib.) as revealed by immunoblotting.
b-Actin was used as a loading control. (g) Rac activity levels in skins from V12RAC1 lines 1 and 2, and WT siblings as determined by G-LISA. The mean of three
independent experiments ±SEM. *Po0.05, one-way analysis of variance (ANOVA).
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evidence of progenitor expansion (unpigmented cells in
dermis, Figure 4d) and melanocyte invasion from an earlier
age compared with V12HRAS-alone animals (Figure 4d,
arrowheads). Taken together, our results suggest that Rac has
a positive role in driving melanoma progression in vivo.
Tiam1 overexpression correlates with increased Rac activity
during melanoma progression
We next investigated whether changes in the expression of a
Rac GEF might also contribute to the increased activity of Rac
observed in the transition from benign to malignant melano-
cyte neoplasia. Sequence similarity searches were used to
identify zebrafish homologs of mammalian Rac GEFs. Putative
orthologs were identified for P-Rex-1, P-Rex-2, -a-Pix, and
Asef. Furthermore, two Tiam1 paralogs and two Stef paralogs
were identified and named Tiam1A and Tiam1B and StefA
and StefB, respectively. Similar to Rac1, all zebrafish homo-
logs showed high degrees of sequence similarity with their
human counterparts (for protein alignments, see
Supplementary Figure S4 online). We then used laser capture
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Figure 4. Active RAC1 promotes tumor nodule formation. (a) Percentage of V12HRAS and V12HRAS::V12RAC1 (lines 1 and 2) animals free from tumors over
time. V12HRAS, n¼ 49; V12HRAS::V12RAC1 line 1, n¼39; V12HRAS::V12RAC1 line 2, n¼ 36. **P¼0.0096, ***P¼ 7.38 107; log rank test. (b) Percentage
of tumors over 3 mm in diameter from V12HRAS and V12HRAS::V12RAC1 animals as in (a). *P¼0.0162, **P¼0.0035; the w2 test. (c, left panels) Transgenic
adult zebrafish expressing V12HRAS only (top panel) or V12HRAS::V12RAC1 (bottom panel). Arrowheads indicate tumor nodules. Bars¼ 1 cm. (c, right panels)
Hematoxylin and eosin (H&E) staining of sections encompassing boxed regions. Scale bars¼ 50mm. (d) H&E staining of sections from animals before tumor nodule
formation. M, muscle; S, skin. Bar¼200mm. Arrowheads indicate invasive melanocytes.
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microscopy to harvest melanocytes from frozen sections
prepared from V600EBRAF-expressing animals (benign) and
from tumor nodules from V12HRAS-expressing animals (VGP)
(Supplementary Figure S5 online). RNA was isolated from
captured cells, reverse transcribed, and linearly amplified to
make a cDNA copy, and subsequently subjected to quantita-
tive real-time PCR (see Materials and Methods). This analysis
revealed significant and selective upregulation of the Rac
GEFs Tiam1B, STEFA, and a-Pix in cells isolated from tumor
nodules (Figure 5a). Immunoblotting confirmed increased
expression of Tiam1 protein in the skin of V12HRAS1-
expressing fish (RGP) and tumor nodules compared with the
skin of V600EBRAF-expressing fish (Figure 5b). Immunohisto-
chemical analysis also corroborated the overexpression of
Tiam1 in 5/5 zebrafish melanoma nodules (see Figure 5c and
Supplementary Figure S6 online). Thus, in zebrafish, Tiam1
expression levels correlate with Rac activity in melanocyte
neoplasms.
To determine whether TIAM1 expression mirrors RAC
activity in human neoplastic melanocytes, we performed
immunoblotting for TIAM1 using protein extracted from the
same panel of benign and malignant cell lines described
above. This revealed correlation between TIAM1 expression
and RAC activity (compare Figure 6a with Figure 2a). How-
ever, immunohistochemical analysis for TIAM1 expression of
our collection of paraffin-embedded neoplasms revealed a
different pattern of TIAM1 staining to that for RAC (summar-
ized in Supplementary Table S1 online). We observed strong
homogeneous TIAM1 staining in all nevocytes from all
categories and cases of nevi, including, notably, dermally
located nevocytes (see representative example of a compound
nevus in Figure 6bi). This is in contrast with the pattern of
staining obtained for total RAC and RAC–GTP, which was
confined to junctional nevocytes. Furthermore, TIAM1 stain-
ing was weak and heterogeneous in the majority of melanoma
samples (Figure 6bii). However, we did note strong homo-
geneous staining for TIAM1 in 3/3 cases of nodular melanoma
(see Figure 6biii for a representative example). This prompted
us to examine TIAM1 expression in an additional 14 cases of
nodular melanoma, all of which demonstrated strong homo-
geneous staining (bringing the total to 17/17). Thus, TIAM1
expression is significantly upregulated in this subtype of
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melanoma compared with all other types (Po0.0001, w2 test).
Thus, our conjecture is that increased TIAM1 expression
activates RAC in subtypes of human melanocytic neoplasm
where there is a marked nodular mode of growth and
invasion. The effect of TIAM1 overexpression on tumor
expansion is possibly limited in nevi by the restriction of
RAC expression to junctional nevocytes, whereas this restric-
tion is lifted in nodular melanoma.
The data presented here support the conclusion that intense
and sustained Rac activation in melanocytes promotes mela-
noma progression rather than initiating melanocyte neoplasia.
Overstimulation of Rac signaling in wild-type and even benign
V600EBRAF-transformed zebrafish melanocytes produced no
outward effect. In contrast, Rac hyperstimulation in Ras-
expressing melanocytes, which are more aberrant than
V600EBRAF-transformed melanocytes, further increased their
proliferation and invasiveness and accelerated progression to
nodular tumors. Forced expression of P29SRAC1 stimulated
the proliferation and motility of primary (nontransformed)
mouse melanocytes (Krauthammer et al., 2012). Potentially,
the P29S mutant in comparison with the G12V mutant used
here acquires functions that allow it to initiate neoplasia.
Alternatively, induction of proliferation and migration may be
less constrained in cultured cells than in melanocytes in vivo.
Treatment of mice bearing melanoma xenografts with Rac
pharmacological inhibitors NSC23766 and EHT1864 potently
inhibited tumor xenograft growth and spread to regional
lymph nodes (Li et al., 2012). Our study indicates that RAC
is likely to be widely involved in human melanoma
pathogenesis and thus supports the candidature of RAC as a
pharmacological target in melanoma treatment.
RAC mutation appears an infrequent mechanism for stimu-
lating RAC in melanomas. We provide evidence here that
RAC overexpression is a common mechanism of RAC hyper-
stimulation in melanoma, as reported elsewhere for other
tumor types (Jordan et al., 1999; Schnelzer et al., 2000; Kamai
et al., 2004; Pan et al., 2004). Mutation and altered expression
of RAC GEFs have been documented in human cancer (Lazer
and Katzav, 2011). Recently, mutated P-REX2, another Dbl
family Rho GEF and a selective activator of RAC, was detected
in a significant fraction of human melanomas (Berger et al.,
2012). Intriguingly, mutations were distributed throughout the
gene and included truncations suggesting inactivation of the
encoded protein. Nonetheless, overexpression of nonsense
and missense P-REX2 mutants acted dominantly to promote
tumorigenicity of oncogenic NRAS-transformed immortalized
human melanocytes. Moreover, deletion of the gene encoding
the related P-Rex1 in mouse resulted in reduced proliferation
and migration of melanoblasts and resultant pigmentation
defects (Lindsay et al., 2011), as observed following Rac1
deletion (Li et al., 2011). Although no less susceptible to
melanoma formation induced by transgenic expression of
oncogenic Nras, P-Rex1-deficient mice developed fewer
metastases and P-Rex1-mediated activation of Rac was
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Figure 6. Upregulation of TIAM1 (T-cell lymphoma invasion and metastasis 1) accompanies increased RAC activity in human melanoma cell lines and malignant
tumor nodules. (a) TIAM1 expression in human melanoma cell lines, immortalized benign melanocytes, and primary melanocytes as revealed by immunoblotting.
TIAM1 expression level normalized to b-actin from the various cell cultures relative to Hermes 2B are indicated beneath these representative western blots
from three independent experiments. (b) TIAM1 expression revealed by immunohistochemical analysis (pink stain) in a representative (i) compound nevus,
(ii) superficial spreading melanoma (SSM), and (iii) nodular malignant melanoma (NMM).
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required for melanoma cell invasion (Lindsay et al., 2011).
Furthermore, similar to TIAM1, P-REX1 is upregulated in
cultured human melanoma cells and frequently in
melanoma tumor samples (Lindsay et al., 2011). Unlike
P-Rex1, Tiam1-deletion is not reported to affect mouse coat
pigmentation, arguing against a physiological role in
melanoblast migration or proliferation. Tiam1 has been
shown to regulate the growth and survival of neoplastic cells
(Malliri et al., 2002b; Rygiel et al., 2008), and these are the
functions it could also be performing in nevocytes at the
epidermal–dermal junction and in malignant melanocytes in
tumor nodules. Perhaps overexpression of TIAM1 or P-REX1
confers distinct patterns of growth on melanoma cells (nodular
malignant melanoma vs. superficial spreading melanoma,
respectively).
MATERIALS AND METHODS
Zebrafish maintenance and generation of transgenic fish
All animal studies described within were approved by the University
of Manchester Ethical Review Board and performed according to UK
Home Office regulations. The V12HRAS, V600EBRAF, and
V12HRAS::Dp85 transgenic lines used in this study have been pre-
viously described (Michailidou et al., 2009). See also Supplementary
Materials online.
Cell culture and transfection
Cell cultures used in this study included HEMn-MP, immortalized
human melanocytes Hermes 2B and Hermes 4A, human embryonic
kidney 293 epithelial cells, as well as wild-type and Tiam1-deficient
mouse embryonic fibroblasts. The human melanoma cell lines used
in this study were A375P, Mel Juso, MM485, SKMEL28 WM-35, WM-
98-1, WM-1158, WM-1361, and WM-2664. See also Supplementary
Materials online for culture and transfection conditions.
Rho GTPase activity assays
G-LISA (Cytoskeleton, Denver, CO) was performed according to the
manufacturer’s instructions. See also Supplementary Materials online.
Pull-down assays to measure GTP-bound levels of Rho GTPases were
performed as previously described (Malliri et al., 2002a).
Immunoblotting
See Supplementary Materials online for a list of primary antibodies
used in this study.
Reverse transcriptase–coupled PCR analysis
Zebrafish embryos were homogenized in QIAzol, and RNA extraction
was performed using the RNeasy Lipid Tissue Mini Kit (QIAGEN,
Hilden, Germany). An on-column DNase digestion step was included
to remove all traces of genomic DNA using the RNase-Free DNase set
(QIAGEN). Omniscript reverse transcriptase (QIAGEN) was then used
to synthesize cDNA, which was added to a standard reaction mix and
subjected to PCR. See also Supplementary Materials online.
Histology and immunostaining
All human studies described within were approved by the University
Hospital Zurich Ethical Review Board. Since in place, the Declaration
of Helsinki Principles were followed and patients gave their written,
informed consent (although certain archive material predates a policy
of obtaining informed consent). See Supplementary Materials online
for primary antibodies used in this study.
Laser capture microscopy, RNA extraction, and cDNA
preparation
Cells of interest from frozen sections were UV-laser microdissected
and captured using the P.A.L.M. system (Zeiss, Oberkochen,
Germany) with a 10 Plan Apochromat objective. Samples were
then processed for RNA extraction using the PicoPure RNA isolation
kit (Molecular Devices, Sunnyvale, CA) and amplification was
achieved using the WT-Ovation Pico RNA amplification system
(NuGEN, Emeryville, CA). See also Supplementary Materials online.
Quantitative real-time PCR
Quantitative real-time PCR amplifications were carried out using
Taqman (Applied Biosystems, Carlsbad, CA)-based PCR with the
Universal Probe Library System (Roche-Applied Science, Penzberg,
Germany) and an ABI 7900HT real time PCR platform (Applied
Biosystems). See also Supplementary Materials including Supple-
mentary Table S2 online for primer sequences and Taqman probes.
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